Loading viewer...
investor_presentation
Format: PDF investor_presentation
LAVA Therapeutics presents its proprietary Gammabody® platform for gamma-delta T cell engagers targeting multiple cancer types including mCRPC, AML, and NSCLC. The company's lead program LAVA-1207 is enrolling in Phase 1/2a trials with strategic partnerships from Pfizer and Johnson & Johnson, backed by $95 million in cash with runway into 2026.
investor_presentation
17 Pages
Ritchie Bros. Auctioneers Incorporated
Olive Resource Capital 2024 Investor Presentation
investor_presentationinvestor_presentation
15 Pages
Olive Resource Capital Inc.
MEG Energy 2016 Investor Presentation
investor_presentationinvestor_presentation
19 Pages
MEG Energy Corporation